Top

Published in:

01-06-2009

Hyponatremia in heart failure

Authors: Dimitrios Farmakis, Gerasimos Filippatos, John Parissis, Dimitrios Th. Kremastinos, Mihai Gheorghiade

Published in: Heart Failure Reviews | Issue 2/2009

Abstract

Hyponatremia is the most common electrolyte abnormality found in hospitalized patients with heart failure. It may occur in patients who have hypovolemic, hypervolemic, or euvolemic state. It is usually not corrected by available therapies. It is a major predictor of prognosis, and correction of hyponatremia can be effectively accomplished by vasopressin antagonists. However, it still remains to be seen whether the normalization of serum sodium with vasopressin antagonists will also lead to an improved long-term prognosis.

Janicic N, Verbalis JG (2003) Evaluation and management of hypo-osmolality in hospitalized patients. Endocrinol Metab Clin North Am 32:459–481. doi:10.1016/S0889-8529(03)00004-5 PubMedCrossRef

Hawkins RC (2003) Age and gender as risk factors for hyponatremia and hypernatremia. Clin Chim Acta 337:169–172. doi:10.1016/j.cccn.2003.08.001 PubMedCrossRef

Adrogué HJ, Madias NE (2000) Hyponatremia. N Engl J Med 342:1581–1589. doi:10.1056/NEJM200005253422107 PubMedCrossRef

Anderson RJ, Chung H-M, Kluge R, Schrier RW (1985) Hyponatremia: a prospective analysis of its epidemiology and the pathogenetic role of vasopressin. Ann Intern Med 102:164–168PubMed

Fall PJ (2000) Hyponatremia and hypernatremia: a systematic approach to causes and their correction. Postgrad Med 107:75–82PubMed

Oren RM (2005) Hyponatremia in congestive heart failure. Am J Cardiol 95:2B–7B. doi:10.1016/j.amjcard.2005.03.002 PubMedCrossRef

Sica DA (2005) Hyponatremia and heart failure—pathophysiology and implications. Congest Heart Fail 11:274–277PubMedCrossRef

Movig KL, Leufkens HG, Lenderink AW, Egberts AC (2003) Validity of hospital discharge International Classification of Diseases (ICD) codes for identifying patients with hyponatremia. J Clin Epidemiol 56:530–535. doi:10.1016/S0895-4356(03)00006-4 PubMedCrossRef

Fried LF, Palevsky PM (1997) Hyponatremia and hypernatremia. Med Clin North Am 81:585–609. doi:10.1016/S0025-7125(05)70535-6 PubMedCrossRef

10.

Klein L, O’Connor CM, Leimberger JD, Gattis-Stough W, Pina IL, Felker GM et al for the OPTIME-CHF investigators (2005) Lower serum sodium is associated with increased short-term mortality in hospitalized patients with worsening heart failure: results from the OPTIME-CHF study. Circulation 111:2454–2460. doi:10.1161/01.CIR.0000165065.82609.3D

11.

Gheorghiade M, Hellkamp AS, Pina IL et al (2005) Hemodynamic characterization and prognostic value of persistent hyponatremia in patients with severe heart failure in the ESCAPE trial. J Am Coll Cardiol 45(suppl):145A [Abstract]

12.

Schrier RW, Abraham WT (1999) Hormones and hemodynamics in heart failure. N Engl J Med 341:577–585. doi:10.1056/NEJM199908193410806 PubMedCrossRef

13.

Schuster VL, Kokko JP, Jacobson HR (1984) Angiotensin II directly stimulates sodium transport in rabbit proximal convoluted tubules. J Clin Invest 73:507–515. doi:10.1172/JCI111237 PubMedCrossRef

14.

Goldsmith SR, Francis GS, Cowley AW Jr (1986) Arginine vasopressin and the renal response to water loading in congestive heart failure. Am J Cardiol 58:295–299. doi:10.1016/0002-9149(86)90065-2 PubMedCrossRef

15.

Schrier RW, Berl T, Anderson RJ (1979) Osmotic and non-osmotic control of vasopressin release. Am J Physiol 236:F321–F332PubMed

16.

Greenberg A (2000) Diuretic complications. Am J Med Sci 319:10–24. doi:10.1097/00000441-200001000-00002 PubMedCrossRef

17.

De Luca L, Klein L, Udelson JE, Orlandi C, Sardella G, Fedele F et al (2005) Hyponatremia in patients with heart failure. Am J Cardiol 96:19L–23L. doi:10.1016/j.amjcard.2005.09.066 PubMed

18.

Chin MH, Goldman L (1996) Correlates of major complications or death in patients admitted to the hospital with congestive heart failure. Arch Intern Med 156:1814–1820. doi:10.1001/archinte.156.16.1814 PubMedCrossRef

19.

Chen MC, Chang HW, Cheng CI, Chen YH, Chai HT (2003) Risk stratification of in-hospital mortality in patients hospitalized for chronic congestive heart failure secondary to non-ischemic cardiomyopathy. Cardiology 100:136–142. doi:10.1159/000073931 PubMedCrossRef

20.

Lee WH, Packer M (1986) Prognostic importance of serum sodium concentration and its modification by converting-enzyme inhibition in patients with severe chronic heart failure. Circulation 73:257–267PubMed

21.

Lee DS, Austin PC, Rouleau JL (2003) Predicting mortality among patients hospitalized for heart failure: derivation and validation of a clinical model. JAMA 290:2581–2587. doi:10.1001/jama.290.19.2581 PubMedCrossRef

22.

Felker GM, Leimberger JD, Califf RM, Cuffe MS, Massie BM, Adams KF Jr et al (2004) Risk stratification after hospitalization for decompensated heart failure. J Card Fail 10:460–466. doi:10.1016/j.cardfail.2004.02.011 PubMedCrossRef

23.

O’Connor CM, Adams KF, Gattis WA et al (2005) Predictors of mortality in patients hospitalized with worsening heart failure: insight from the ACTIV in CHF trial. J Am Coll Cardiol 45(suppl):151A [Abstract]

24.

Rich MW, Beckham V, Wittenberg C, Leven CL, Freedland KE, Carney RM (1995) A multidisciplinary intervention to prevent the readmission of elderly patients with congestive heart failure. N Engl J Med 333:1190–1195. doi:10.1056/NEJM199511023331806 PubMedCrossRef

25.

Krumholz HM, Chen YT, Bradford WD, Cerese J (1999) Variations in and correlates of length of stay in academic hospitals among patients with heart failure resulting from systolic dysfunction. Am J Manag Care 5:715–723PubMed

26.

Kearney MT, Fox KA, Lee AJ, Brooksby WP, Shah AM, Flapan A et al (2004) Predicting sudden death in patients with mild to moderate chronic heart failure. Heart 90:1137–1143. doi:10.1136/hrt.2003.021733 PubMedCrossRef

27.

Cuffe MS, Califf RM, Adams KF Jr, Benza R, Bourge R, Colucci WS et al (2002) Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. JAMA 287:1541–1547. doi:10.1001/jama.287.12.1541 PubMedCrossRef

28.

Gheorghiade M, Gattis WA, O’Connor CM, Adams KF Jr, Elkayam U, Barbagelata A et al & Acute and Chronic Therapeutic Impact of a Vasopressin Antagonist in Congestive Heart Failure (ACTIV in CHF) Investigators (2004) Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial. JAMA 291:1963–1971. doi:10.1001/jama.291.16.1963

29.

Binanay C, Califf RM, Hasselblad V, O’Connor CM, Shah MR, Sopko G et al & ESCAPE Investigators and ESCAPE Study Coordinators (2005) Evaluation study of congestive heart failure and pulmonary artery catheterization effectiveness: the ESCAPE trial. JAMA 294:1625–1633. doi:10.1001/jama.294.13.1625

30.

Lilly LS, Dzau VJ, Williams GH, Rydstedt L, Hollenberg NK (1984) Hyponatremia in congestive heart failure: implications for neurohormonal activation and responses to orthostasis. J Clin Endocrinol Metab 59:924–930PubMedCrossRef

31.

Dzau VJ, Packer M, Lilly LS, Swartz SL, Hollenberg NK, Williams GH (1984) Prostaglandins in severe congestive heart failure: relation to activation of the renin-angiotensin system and hyponatremia. N Engl J Med 310:347–352PubMed

32.

Brater C (2000) Diuretic therapy in congestive heart failure. Congest Heart Fail 6:197–201PubMed

33.

Rai A, Whaley-Connell A, McFarlane S, Sowers JR (2006) Hyponatremia, arginine vasopressin dysregulation, and vasopressin receptor antagonism. Am J Nephrol 26:579–589. doi:10.1159/000098028 PubMedCrossRef

34.

Quittnat F, Gross P (2006) Vaptans and the treatment of water-retaining disorders. Semin Nephrol 26:234–243. doi:10.1016/j.semnephrol.2006.02.003 PubMedCrossRef

35.

Ghali JK, Koren MJ, Taylor JR, Brooks-Asplund E, Fan K, Long WA et al (2006) Efficacy and safety of oral conivaptan: a V1A/V2 vasopressin receptor antagonist, assessed in a randomized, placebo-controlled trial in patients with euvolemic or hypervolemic hyponatremia. J Clin Endocrinol Metab 91:2145–2152. doi:10.1210/jc.2005-2287 PubMedCrossRef

36.

Schrier RW, Gross P, Gheorghiade M, Berl T, Verbalis JG, Czerwiec FS et al; SALT Investigators (2006) Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med 355:2099–2112. doi:10.1056/NEJMoa065181

37.

Gheorghiade M, Konstam MA, Burnett JC Jr et al (2007) Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials. JAMA 297:1332–1343. doi:10.1001/jama.297.12.1332 PubMedCrossRef

38.

Konstam MA, Gheorghiade M, Burnett JC Jr et al (2007) Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA 297:1319–1331. doi:10.1001/jama.297.12.1319 PubMedCrossRef

39.

Abraham WT, Shamshirsaz AA, McFann K, Oren RM, Schrier RW (2006) Aquaretic effect of lixivaptan, an oral, non-peptide, selective V2 receptor vasopressin antagonist, in New York Heart Association functional class II and III chronic heart failure patients. J Am Coll Cardiol 47:1615–1621. doi:10.1016/j.jacc.2005.11.071 PubMedCrossRef

40.

Rossi J, Bayram M, Udelson JE et al (2007) Improvement in hyponatremia during hospitalization for worsening heart failure is associated with improved outcomes: insights from the Acute and Chronic Therapeutic Impact of a Vasopressin Antagonist in Chronic Heart Failure (ACTIV in CHF) trial. Acute Card Care 9(2):82–86. doi:10.1080/17482940701210179 PubMedCrossRef

Title: Hyponatremia in heart failure
Authors: Dimitrios Farmakis
Gerasimos Filippatos
John Parissis
Dimitrios Th. Kremastinos
Mihai Gheorghiade
Publication date: 01-06-2009
Publisher: Springer US
Published in: Heart Failure Reviews / Issue 2/2009
Print ISSN: 1382-4147
Electronic ISSN: 1573-7322
DOI: https://doi.org/10.1007/s10741-008-9109-7

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Hyponatremia in heart failure

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2009

Introduction: vasopressin therapy